TEVA Gets Shot of Good News
TEVA's patents on Copaxone will be protected until 2015, resulting in additional billion in profits for the drug maker.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
